Chronic Pain Treatment Market Report 2026

The chronic pain treatment market size has grown strongly in recent years. It will grow from $109.05 billion in 2025 to $119.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to opioid usage, musculoskeletal disorders, aging population, hospital pain clinics, post-surgical pain management.

The chronic pain treatment market size is expected to see strong growth in the next few years. It will grow to $168.99 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to opioid regulation, device-based therapies, chronic disease prevalence, mental health integration, outpatient pain care growth. Major trends in the forecast period include shift toward non-opioid pain therapies, growth of neuromodulation devices, expansion of multidisciplinary pain management, increased focus on personalized pain care, integration of psychological support therapies.

The rising prevalence of arthritis pain is expected to drive the growth of the chronic pain treatment market in the coming years. Arthritis pain refers to discomfort, soreness, or aching in the joints caused by inflammation or degeneration associated with arthritis. The prevalence of arthritis pain is increasing primarily due to the aging population, as joint wear and tear naturally rise with age, resulting in a higher incidence of arthritis-related conditions. Chronic pain treatments address arthritis pain by targeting inflammation and nerve sensitivity, helping reduce discomfort, improve joint function, and enhance overall quality of life for individuals with persistent symptoms. For instance, in July 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, an estimated 21.2% of adults aged 18 and older in the United States were diagnosed with arthritis in 2023. Therefore, the rising prevalence of arthritis pain is driving the growth of the chronic pain treatment market.

Major companies in the chronic pain treatment market are focusing on developing advanced solutions, such as closed-loop spinal cord stimulation (SCS) systems, to meet growing demand for non-opioid therapies, provide better long-term pain control, and improve patient outcomes. Closed-loop SCS systems are implantable, rechargeable neurostimulators that continuously sense neural signals and automatically adjust electrical stimulation in real time, unlike traditional open-loop devices that deliver preset outputs. For instance, in April 2024, Medtronic plc, an Ireland-based medical device company, received U.S. Food and Drug Administration (FDA) approval for the Inceptiv Neurostimulation System. This compact implantable device monitors evoked neural responses using sensing electrodes and automatically adjusts stimulation. It provides full-body 1.5T and 3T MRI compatibility, features impedance-independent sensing, and is indicated for chronic, intractable trunk or limb pain. The system delivers more consistent pain relief, better responder outcomes, and improved comfort compared with traditional fixed-output SCS systems.

In May 2025, electroCore Inc., a US-based bioelectronic technology company, acquired NeuroMetrix Inc. for an undisclosed amount. Through this acquisition, electroCore aims to strengthen its position in the non-invasive bioelectronic therapy market by integrating NeuroMetrix’s Quell platform, expanding product offerings, and accelerating growth in the chronic pain and wellness segments, particularly within the Veterans Affairs Hospital System. NeuroMetrix Inc. is a US-based medical technology company specializing in non-invasive therapeutic devices for chronic pain conditions such as fibromyalgia.

Major companies operating in the chronic pain treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Mallinckrodt plc, Nevro Corp.

North America was the largest region in the chronic pain treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pain treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic pain treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the chronic pain treatment market by impacting imports of pain-relief drugs, neuromodulation devices, and implantable pain management systems. Device-based therapies and advanced pharmaceuticals are most affected, particularly in North America and Europe due to reliance on global medical device supply chains. Hospitals and clinics experience higher treatment expenses. However, tariffs are promoting domestic production of pain management drugs and devices, improving long-term market stability.

The chronic pain treatment market research report is one of a series of new reports that provides chronic pain treatment market statistics, including chronic pain treatment industry global market size, regional shares, competitors with a chronic pain treatment market share, detailed chronic pain treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pain treatment industry. This chronic pain treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic pain treatment refers to the ongoing management of pain that lasts for more than three months, often extending beyond the expected healing period. It typically involves a combination of medications, physical therapy, psychological support, and lifestyle modifications to reduce pain, improve function, and enhance quality of life.

The main product types for chronic pain include drugs and devices. Drugs for chronic pain target inflammation, nerve signals, or underlying causes to relieve persistent pain and improve patient well-being. They are used for conditions such as neuropathic pain, arthritis, chronic back pain, cancer pain, migraines, fibromyalgia, and others. These medications are distributed through direct and indirect channels and serve a range of end-users, including hospitals, clinics, nursing homes, research centers, universities, and more.

The chronic pain treatment market consists of revenues earned by entities by providing services such as pharmacological treatment, physical therapy, psychological counseling, interventional pain management, alternative therapies, pain management clinics, and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pain treatment market also includes sales of lyrica, cymbalta, oxycontin, neurontin, voltaren gel, quell, and precision spectra spinal cord stimulator. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.